Page last updated: 2024-08-17

quinoxalines and xl765

quinoxalines has been researched along with xl765 in 24 studies

Research

Studies (24)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's22 (91.67)24.3611
2020's2 (8.33)2.80

Authors

AuthorsStudies
Belousov, R; Brewer, KJ; Ghadimi, MP; Hoffman, A; Lazar, AJ; Lev, D; Liu, J; Lopez, G; Lusby, K; Pollock, RE; Torres, KE; Young, ED1
Bao, X; Cai, F; Dai, C; Feng, M; Guo, K; Li, G; Lian, W; Liu, X; Ma, S; Ma, W; Wang, J; Wang, R; Xiao, J; Xing, B; Yang, Y; Yao, Y; Zhang, B; Zhang, H1
Cohen, RB; Engelman, JA; Felip, E; Jänne, PA; Laird, AD; Macé, S; Martinez, P; Rockich, K; Ruiz-Soto, R; Shapiro, GI; Xu, J1
Baselga, J; Egile, C; Laird, AD; Lorusso, PM; Markman, B; Miles, D; Papadopoulos, KP; Patnaik, A; Ruiz-Soto, R; Shi, W; Tabernero, J; Tolcher, AW1
Abulafia, W; Bentzien, F; Buhr, CA; Chen, J; Chu, F; Dale, S; Du, X; Foster, P; Hsu, PP; Jaeger, CT; Laird, AD; Lam, ST; Lamb, P; Lee, M; Matthews, DJ; Plonowski, A; Qian, F; Shen, P; Won, KA; Wu, J; Yakes, FM; Yamaguchi, K; Young, J; Yu, P; Zhang, W1
Abrisqueta, P; Bentzien, F; Egile, C; Jiang, J; Papadopoulos, KP; Rasco, D; Ruiz-Soto, R; Shi, W; Tabernero, J; Vose, JM1
Ahluwalia, MS; Cloughesy, TF; Egile, C; Fathallah-Shaykh, HM; Jiang, J; Lager, JJ; Laird, AD; Mohile, N; Omuro, A; Tang, J; Wen, PY1
Arimoto, T; Fujii, T; Fukuda, T; Ikeda, Y; Inaba, K; Kashiyama, T; Kawana, K; Kuramoto, H; Miyasaka, A; Oda, K; Osuga, Y; Sone, K; Uehara, Y; Wada-Hiraike, O; Yano, T1
Boratyn, E; Durbas, M; Horwacik, I; Kamycka, E; Rokita, H1
Colapietro, A; Festuccia, C; Gravina, GL; Jitariuc, A; Mancini, A; Marampon, F; Ricevuto, E; Scarsella, L; Vitale, F1
Baars, JW; de Rooij, MF; Egile, C; Eldering, E; Jansen, MH; Kater, AP; Kersten, MJ; Kuijpers, TW; Kuil, A; Spaargaren, M; Ter Burg, J; Thijssen, R; van Bochove, GG; van Oers, MH; Virone-Oddos, A1
Blackwell, K; Burris, H; Campana, F; Gao, L; Gomez, P; Isakoff, S; Jiang, J; Lynn Henry, N; Macé, S; Tolaney, SM1
Aoki, K; Arimoto, T; Fujii, T; Fukuda, T; Ikeda, Y; Inaba, K; Kashiyama, T; Kawana, K; Makii, C; Miyasaka, A; Oda, K; Osuga, Y; Sone, K; Wada-Hiraike, O; Yano, T1
Awan, FT; Costa, LJ; Gao, L; Gore, L; Lager, J; Sharma, J1
Camisa, H; Dedieu, JF; Edelman, G; Ghuysen, AF; Lager, J; Liu, L; LoRusso, PM; Mehnert, JM; Sharma, J; Stein, M1
Munakata, W; Tobinai, K1
Ailawadhi, S; Arnason, J; Brown, JR; Doorduijn, JK; Egile, C; Gabrail, NY; Ganguly, S; Gao, L; Hamadani, M; Hayslip, J; Janssens, A; Kasar, S; Kater, AP; Kersten, MJ; Lager, JJ; Millenson, M; Offner, F; Ottmann, O; Tilly, H; Wagner-Johnston, N; Wu, B1
Chen, T; Jin, M; Khishignyam, T; Kong, D; Qiu, Y; Wang, R; Wang, Z; Zhang, L; Zhang, Z; Zhou, C1
Campana, F; Damstrup, L; Gandhi, L; Grande, E; Heist, RS; Hidalgo, M; Hyman, DM; Mita, MM; Schram, AM1
Chen, SN; He, C; Wang, Q; Wu, P; Zhang, R1
Rehan, M1
Batsios, G; Gillespie, AM; Molloy, AR; Najac, C; Pieper, RO; Ronen, SM; Santos, RD; Subramani, E; Viswanath, P1
Arend, RC; Birrer, MJ; Chimiczewski, P; Davis, AM; Ghamande, S; O'Malley, DM; Provencher, D; Vergote, I1
Bertoni, F; Lupia, A; Stathis, A; Tarantelli, C1

Reviews

1 review(s) available for quinoxalines and xl765

ArticleYear
Is There a Role for Dual PI3K/mTOR Inhibitors for Patients Affected with Lymphoma?
    International journal of molecular sciences, 2020, Feb-05, Volume: 21, Issue:3

    Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Chromones; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma; Molecular Targeted Therapy; Oligopeptides; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Quinoxalines; Signal Transduction; Sulfonamides; TOR Serine-Threonine Kinases

2020

Trials

10 trial(s) available for quinoxalines and xl765

ArticleYear
Phase I safety and pharmacokinetic study of the PI3K/mTOR inhibitor SAR245409 (XL765) in combination with erlotinib in patients with advanced solid tumors.
    Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2014, Volume: 9, Issue:3

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cohort Studies; ErbB Receptors; Erlotinib Hydrochloride; Female; Follow-Up Studies; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Neoplasms; Phosphoinositide-3 Kinase Inhibitors; Prognosis; Protein Kinase Inhibitors; Quinazolines; Quinoxalines; Safety; Sulfonamides; Survival Rate; Tissue Distribution; TOR Serine-Threonine Kinases

2014
Phase I safety, pharmacokinetic, and pharmacodynamic study of SAR245409 (XL765), a novel, orally administered PI3K/mTOR inhibitor in patients with advanced solid tumors.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2014, May-01, Volume: 20, Issue:9

    Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Drug Monitoring; Female; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Neoplasms; Phosphoinositide-3 Kinase Inhibitors; Quinoxalines; Signal Transduction; Sulfonamides; TOR Serine-Threonine Kinases; Treatment Outcome; Young Adult

2014
Efficacy, safety, pharmacokinetics and pharmacodynamics of SAR245409 (voxtalisib, XL765), an orally administered phosphoinositide 3-kinase/mammalian target of rapamycin inhibitor: a phase 1 expansion cohort in patients with relapsed or refractory lymphoma
    Leukemia & lymphoma, 2015, Volume: 56, Issue:6

    Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Anemia; Area Under Curve; Diarrhea; Drug Resistance, Neoplasm; Exanthema; Female; Humans; Lymphoma; Male; MAP Kinase Signaling System; Metabolic Clearance Rate; Middle Aged; Nausea; Neoplasm Recurrence, Local; Phosphoinositide-3 Kinase Inhibitors; Quinoxalines; Remission Induction; Sulfonamides; TOR Serine-Threonine Kinases; Treatment Outcome; Young Adult

2015
Phase I dose-escalation study of the PI3K/mTOR inhibitor voxtalisib (SAR245409, XL765) plus temozolomide with or without radiotherapy in patients with high-grade glioma.
    Neuro-oncology, 2015, Volume: 17, Issue:9

    Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents; Brain Neoplasms; Dacarbazine; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Glioma; Humans; Male; Middle Aged; Phosphoinositide-3 Kinase Inhibitors; Quinoxalines; Sulfonamides; Temozolomide; TOR Serine-Threonine Kinases; Treatment Outcome

2015
Phase I/II dose-escalation study of PI3K inhibitors pilaralisib or voxtalisib in combination with letrozole in patients with hormone-receptor-positive and HER2-negative metastatic breast cancer refractory to a non-steroidal aromatase inhibitor.
    Breast cancer research and treatment, 2015, Volume: 154, Issue:2

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Drug Resistance, Neoplasm; Female; Humans; Letrozole; Maximum Tolerated Dose; Middle Aged; Mutation; Neoplasm Grading; Neoplasm Staging; Nitriles; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Quinoxalines; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Retreatment; Sulfonamides; Treatment Outcome; Triazoles

2015
Phase Ib trial of the PI3K/mTOR inhibitor voxtalisib (SAR245409) in combination with chemoimmunotherapy in patients with relapsed or refractory B-cell malignancies.
    British journal of haematology, 2016, Volume: 175, Issue:1

    Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Drug Administration Schedule; Drug Monitoring; Drug Resistance, Neoplasm; Female; Humans; Leukemia, B-Cell; Lymphoma, B-Cell; Male; Maximum Tolerated Dose; Middle Aged; Phosphoinositide-3 Kinase Inhibitors; Quinoxalines; Recurrence; Retreatment; Rituximab; Sulfonamides; TOR Serine-Threonine Kinases; Treatment Outcome

2016
A phase I dose-escalation study of the safety and pharmacokinetics of a tablet formulation of voxtalisib, a phosphoinositide 3-kinase inhibitor, in patients with solid tumors.
    Investigational new drugs, 2018, Volume: 36, Issue:1

    Topics: Adult; Aged; Antineoplastic Agents; Female; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Phosphoinositide-3 Kinase Inhibitors; Quinoxalines; Sulfonamides; Tablets

2018
Voxtalisib (XL765) in patients with relapsed or refractory non-Hodgkin lymphoma or chronic lymphocytic leukaemia: an open-label, phase 2 trial.
    The Lancet. Haematology, 2018, Volume: 5, Issue:4

    Topics: Cohort Studies; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Non-Hodgkin; Male; Quinoxalines; Sulfonamides

2018
A phase Ib dose-escalation and expansion study of the oral MEK inhibitor pimasertib and PI3K/MTOR inhibitor voxtalisib in patients with advanced solid tumours.
    British journal of cancer, 2018, Volume: 119, Issue:12

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Female; Humans; Male; Middle Aged; Mitogen-Activated Protein Kinase Kinases; Neoplasms; Niacinamide; Phosphoinositide-3 Kinase Inhibitors; Quinoxalines; Sulfonamides; TOR Serine-Threonine Kinases

2018
EMR 20006-012: A phase II randomized double-blind placebo controlled trial comparing the combination of pimasertib (MEK inhibitor) with SAR245409 (PI3K inhibitor) to pimasertib alone in patients with previously treated unresectable borderline or low grade
    Gynecologic oncology, 2020, Volume: 156, Issue:2

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Double-Blind Method; Female; Humans; MAP Kinase Kinase 1; MAP Kinase Kinase 2; Middle Aged; Neoplasm Grading; Neoplasm Recurrence, Local; Neoplasm Staging; Niacinamide; Ovarian Neoplasms; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Protein Kinase Inhibitors; Quinoxalines; Sulfonamides; TOR Serine-Threonine Kinases; Young Adult

2020

Other Studies

13 other study(ies) available for quinoxalines and xl765

ArticleYear
Targeting the PI3K/mTOR axis, alone and in combination with autophagy blockade, for the treatment of malignant peripheral nerve sheath tumors.
    Molecular cancer therapeutics, 2012, Volume: 11, Issue:8

    Topics: Animals; Antineoplastic Agents; Apoptosis; Autophagy; Cell Line, Tumor; Cell Proliferation; Enzyme Inhibitors; Humans; Mice; Nerve Sheath Neoplasms; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Quinoxalines; Signal Transduction; Sulfonamides; TOR Serine-Threonine Kinases; Tumor Burden; Xenograft Model Antitumor Assays

2012
Inhibition of PI3K/AKT/mTOR pathway enhances temozolomide-induced cytotoxicity in pituitary adenoma cell lines in vitro and xenografted pituitary adenoma in female nude mice.
    Endocrinology, 2013, Volume: 154, Issue:3

    Topics: Adenoma; Animals; Antineoplastic Agents, Alkylating; Apoptosis; Cell Line, Tumor; Cell Proliferation; Dacarbazine; Drug Synergism; Drug Therapy, Combination; Female; Human Growth Hormone; Humans; Mice; Mice, Nude; Phosphoinositide-3 Kinase Inhibitors; Pituitary Neoplasms; Prolactin; Proto-Oncogene Proteins c-akt; Quinoxalines; Signal Transduction; Sulfonamides; Temozolomide; TOR Serine-Threonine Kinases; Xenograft Model Antitumor Assays

2013
Characterization of the activity of the PI3K/mTOR inhibitor XL765 (SAR245409) in tumor models with diverse genetic alterations affecting the PI3K pathway.
    Molecular cancer therapeutics, 2014, Volume: 13, Issue:5

    Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Movement; Disease Models, Animal; Humans; Inhibitory Concentration 50; Mice; Neoplasms; Neovascularization, Pathologic; Phosphatidylinositol Phosphates; Phosphoinositide-3 Kinase Inhibitors; Phosphorylation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Quinoxalines; Ribosomal Protein S6 Kinases; Signal Transduction; Sulfonamides; TOR Serine-Threonine Kinases; Xenograft Model Antitumor Assays

2014
Antitumor activity of a combination of dual PI3K/mTOR inhibitor SAR245409 and selective MEK1/2 inhibitor pimasertib in endometrial carcinomas.
    Gynecologic oncology, 2015, Volume: 138, Issue:2

    Topics: Antineoplastic Combined Chemotherapy Protocols; Cell Growth Processes; Cell Line, Tumor; Drug Synergism; Endometrial Neoplasms; Female; Humans; MAP Kinase Kinase 1; MAP Kinase Kinase 2; MAP Kinase Signaling System; Molecular Targeted Therapy; Niacinamide; Phosphoinositide-3 Kinase Inhibitors; Protein Kinase Inhibitors; Quinoxalines; Sulfonamides; TOR Serine-Threonine Kinases

2015
GD2 ganglioside specific antibody treatment downregulates PI3K/Akt/mTOR signaling network in human neuroblastoma cell lines.
    International journal of oncology, 2015, Volume: 47, Issue:3

    Topics: Antibodies, Monoclonal; Apoptosis; Cell Line, Tumor; Drug Synergism; Gangliosides; Gene Expression Regulation, Neoplastic; Humans; Imidazoles; Neuroblastoma; Phosphatidylinositol 3-Kinases; Phosphorylcholine; Proto-Oncogene Proteins c-akt; Quinolines; Quinoxalines; Signal Transduction; Sulfonamides; TOR Serine-Threonine Kinases

2015
Dual PI3K/mTOR inhibitor, XL765 (SAR245409), shows superior effects to sole PI3K [XL147 (SAR245408)] or mTOR [rapamycin] inhibition in prostate cancer cell models.
    Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine, 2016, Volume: 37, Issue:1

    Topics: Apoptosis; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Forkhead Box Protein O1; Glycogen Synthase Kinase 3 beta; Humans; Inhibitory Concentration 50; Male; Phosphoinositide-3 Kinase Inhibitors; Prostatic Neoplasms; Quinoxalines; Receptors, Androgen; RNA, Small Interfering; Sirolimus; Sulfonamides; TOR Serine-Threonine Kinases

2016
The pan phosphoinositide 3-kinase/mammalian target of rapamycin inhibitor SAR245409 (voxtalisib/XL765) blocks survival, adhesion and proliferation of primary chronic lymphocytic leukemia cells.
    Leukemia, 2016, Volume: 30, Issue:2

    Topics: Adolescent; Adult; CD40 Antigens; Cell Adhesion; Cell Proliferation; Cell Survival; Cytokines; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Middle Aged; Phosphoinositide-3 Kinase Inhibitors; Purines; Quinazolinones; Quinoxalines; Sulfonamides; T-Lymphocytes; TOR Serine-Threonine Kinases

2016
Synergistic antitumor effects of combination PI3K/mTOR and MEK inhibition (SAR245409 and pimasertib) in mucinous ovarian carcinoma cells by fluorescence resonance energy transfer imaging.
    Oncotarget, 2016, May-17, Volume: 7, Issue:20

    Topics: Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Cystadenocarcinoma, Mucinous; Drug Screening Assays, Antitumor; Drug Synergism; Female; Fluorescence Resonance Energy Transfer; Humans; MAP Kinase Kinase Kinases; Models, Theoretical; Niacinamide; Ovarian Neoplasms; Phosphoinositide-3 Kinase Inhibitors; Quinoxalines; Sulfonamides; TOR Serine-Threonine Kinases

2016
Clinical development of voxtalisib: a pan-PI3K/mTOR inhibitor.
    The Lancet. Haematology, 2018, Volume: 5, Issue:4

    Topics: Clinical Trials as Topic; Drug Discovery; Humans; Phosphoinositide-3 Kinase Inhibitors; Quinoxalines; Signal Transduction; Sulfonamides; TOR Serine-Threonine Kinases

2018
In vitro anti-leukemia activity of dual PI3K/mTOR inhibitor Voxtalisib on HL60 and K562 cells, as well as their multidrug resistance counterparts HL60/ADR and K562/A02 cells.
    Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 2018, Volume: 103

    Topics: Antineoplastic Agents; Cell Culture Techniques; Cell Cycle Checkpoints; Cell Proliferation; Cell Survival; Doxorubicin; Drug Resistance, Multiple; Drug Resistance, Neoplasm; HL-60 Cells; Humans; K562 Cells; Phosphoinositide-3 Kinase Inhibitors; Quinoxalines; Signal Transduction; Sulfonamides; TOR Serine-Threonine Kinases

2018
[Effect of PI3K/mTOR Signal Pathway Inhibitor XL765 on Human Leukemic KG-1 Cells].
    Zhongguo shi yan xue ye xue za zhi, 2019, Volume: 27, Issue:3

    Topics: Apoptosis; Cell Line, Tumor; Humans; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins c-akt; Quinoxalines; Signal Transduction; Sulfonamides; TOR Serine-Threonine Kinases

2019
Anticancer compound XL765 as PI3K/mTOR dual inhibitor: A structural insight into the inhibitory mechanism using computational approaches.
    PloS one, 2019, Volume: 14, Issue:6

    Topics: Binding Sites; Catalytic Domain; Class Ib Phosphatidylinositol 3-Kinase; Computer Simulation; Drug Screening Assays, Antitumor; Humans; Lysine; Methionine; Models, Molecular; Molecular Docking Simulation; Molecular Structure; Quinoxalines; Sulfonamides; TOR Serine-Threonine Kinases

2019
PI3K/mTOR inhibition of IDH1 mutant glioma leads to reduced 2HG production that is associated with increased survival.
    Scientific reports, 2019, 07-19, Volume: 9, Issue:1

    Topics: Adaptor Proteins, Signal Transducing; Animals; Astrocytes; Brain Neoplasms; Cell Cycle Proteins; Cell Line, Transformed; Glioma; Glucose; Glutamine; Glutarates; Humans; Isocitrate Dehydrogenase; Kaplan-Meier Estimate; Mice; Neoplasm Proteins; Nuclear Magnetic Resonance, Biomolecular; Phosphatidylinositol 3-Kinases; Phosphorylation; Protein Processing, Post-Translational; Quinoxalines; Ribosomal Protein S6 Kinases; Signal Transduction; Sulfonamides; TOR Serine-Threonine Kinases; Xenograft Model Antitumor Assays

2019